Ribo Newsroom
-
Ribo Showcases New Clinical Data from Leading siRNA Programs at ESC 2025, Underscoring Significant Progress and Achievements in Advancing Cardiovascular TherapiesRibo and Ribocure Pharmaceuticals AB presented four key scientific findings at the 2025 European Society of Cardiology (ESC) Congress in Madrid, Spain, underscoring significant progress in siRNA-based cardiovascular therapeutics pipeline.September 10, 2025 -
Ribo Secures Series E Funding to Accelerate Global siRNA Therapeutics StrategyRibo secures series E funding to accelerate global siRNA therapeutics strategyJuly 21, 2025 -
Ribo's International R&D Center Ribocure Closes USD 33 Million Equity Financing to Accelerate Innovative siRNA Drug DevelopmentThe International R&D Center Ribocure closes USD 33 Million equity financing round.July 16, 2025 -
Ribo Announces siRNA-based Treatment of Autoimmune Diseases (RBD2080) Received Clinical Approval in AustraliaRibo Announces siRNA-based Treatment of Autoimmune Diseases (RBD2080) Received Clinical Approval in AustraliaFebruary 26, 2025 -
First Milestone Successfully Achieved in Ribo’s Collaboration in Liver Diseases With Boehringer IngelheimFirst Milestone Successfully Achieved in Ribo’s Collaboration in Liver Diseases With Boehringer IngelheimJanuary 10, 2025 -
Ribo and Pheiron enter strategic collaboration for AI-assisted drug development of RNA therapeuticsSeptember 24, 2024